• September 18, 2019

Hansoh Pharma and Atomwise Launch Strategic AI Drug Discovery Collaboration for Multiple Therapeutic Areas - Odessa American: Business

e-Edition Subscribe

Hansoh Pharma and Atomwise Launch Strategic AI Drug Discovery Collaboration for Multiple Therapeutic Areas

Print
Font Size:
Default font size
Larger font size

Posted: Wednesday, September 11, 2019 7:38 pm

SHANGHAI & SAN FRANCISCO--(BUSINESS WIRE)--Sep 11, 2019--

Hansoh Pharmaceutical Group Company Limited (“ Hansoh Pharma ”), a leading biopharmaceutical company in China, and Atomwise, Inc. (“ Atomwise ”), the leader in artificial intelligence (AI) for drug discovery, have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190911005825/en/

Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of complementary expertise and technologies has the potential to dramatically increase success and compress timelines for drug discovery and clinical development.

“Atomwise is the right partner for Hansoh Pharma to innovate using AI technology and generate a diverse pipeline of small molecules for oncology and other therapeutic areas,” said Aifeng Lyu, Ph.D., President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma. “We have been very impressed by Atomwise’s AI platform, capabilities, and team, and by working together we believe there are exceptional opportunities to develop first in-class and best in-class therapies.”

“We are excited to partner with Hansoh Pharma, the leading biopharma in China,” said Dr. Abraham Heifets, CEO of Atomwise. “Hansoh Pharma shares our strong commitment to innovation and mission for global impact on patient health” he added.

Atomwise’s world-class AI platform for structure-based drug design will direct hit discovery, hit-to-lead selection, and lead optimization efforts. Hansoh Pharma will contribute its capabilities in biological assays and medicinal chemistry, as well as lead subsequent preclinical and clinical development activities.

Under the terms of the collaboration, Atomwise will receive undisclosed technology access fees, option exercise fees, royalties, and income based on sublicensing or sale of assets created under the collaboration. Based on historical average revenues for small molecule drugs, the total potential value of the deal to Atomwise with success in all projects could be in excess of blockbuster potential. Hansoh Pharma will receive rights for development and commercialization in all fields and geographies.

About Hansoh Pharma

Hansoh Pharma (3692:HK) is a leading biopharmaceutical company in China committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders, together with its approximately 8,900 employees. Founded in 1995, Hansoh has fully integrated research and development, manufacturing and commercial capabilities, supporting a leadership position in central nervous system (CNS), oncology, anti-infectives and diabetes, among others. With approximately 1,400 professionals across R&D, Hansoh ranks top 2 in innovation among all biotech and pharmaceutical companies in China based on new molecular entity INDs submitted for clinical development since 2011. Hansoh Pharma’s 2018 revenue was approximately US$1.1 billion, representing a year-over-year growth of 25%. For more information, please visit www.hspharm.com.

About Atomwise

Atomwise, Inc. invented the first deep learning AI technology for structure-based small molecule drug discovery. Created in 2012, today Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than one hundred universities and hospitals in 19 countries. Atomwise has raised over $50 million from leading venture capital firms to support the development and application of its AI technology.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190911005825/en/

CONTACT: Hansoh Pharma

Name: Paul Lu

Email:communications@hspharm.comAtomwise

Name: Sara Dunn

Email:SDunn@jpa.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA ASIA PACIFIC CHINA

INDUSTRY KEYWORD: BIOTECHNOLOGY SOFTWARE PHARMACEUTICAL ONCOLOGY HEALTH TECHNOLOGY

SOURCE: Atomwise

Copyright Business Wire 2019.

PUB: 09/11/2019 08:38 PM/DISC: 09/11/2019 08:38 PM

http://www.businesswire.com/news/home/20190911005825/en

© 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Clear
70°
Humidity: 62%
Winds: SE at 5mph
Feels Like: 70°

Your Extended Forecast

Tomorrow

weather
High 95°/Low 70°
Plenty of sun. Highs in the mid 90s and lows in the low 70s.

thursday

weather
High 93°/Low 69°
Plenty of sun. Highs in the low 90s and lows in the upper 60s.

friday

weather
High 92°/Low 71°
Mostly sunny. Highs in the low 90s and lows in the low 70s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7670 to sign up today.